New eye injection enters human testing to fight leading cause of blindness
NCT ID NCT05456828
Summary
This is the first study in people testing a new drug called ASKG712, given as an injection into the eye, for wet age-related macular degeneration (AMD). The main goal is to find out if different doses are safe and how the body processes the drug. Researchers will also check if the treatment helps improve or stabilize vision in the 56 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOVASCULAR AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai General Hospital
Shanghai, Shanghai Municipality, China
Conditions
Explore the condition pages connected to this study.